160 related articles for article (PubMed ID: 17877516)
21. Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease.
Xin H; Fischer C; Schwab M; Klotz U
Aliment Pharmacol Ther; 2005 May; 21(9):1105-9. PubMed ID: 15854172
[TBL] [Abstract][Full Text] [Related]
22. Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine.
Buster EH; van Vuuren HJ; Zondervan PE; Metselaar HJ; Tilanus HW; de Man RA
Eur J Gastroenterol Hepatol; 2008 Jan; 20(1):68-72. PubMed ID: 18090994
[TBL] [Abstract][Full Text] [Related]
23. Thiopurine therapy: when to start and when to stop.
McGovern DP; Travis SP
Eur J Gastroenterol Hepatol; 2003 Mar; 15(3):219-23. PubMed ID: 12610314
[TBL] [Abstract][Full Text] [Related]
24. Azathioprine-associated acute myeloid leukemia in a patient with Crohn's disease and thiopurine S-methyltransferase deficiency.
Yenson PR; Forrest D; Schmiegelow K; Dalal BI
Am J Hematol; 2008 Jan; 83(1):80-3. PubMed ID: 17696202
[TBL] [Abstract][Full Text] [Related]
25. Review article: practical management of inflammatory bowel disease patients taking immunomodulators.
Siegel CA; Sands BE
Aliment Pharmacol Ther; 2005 Jul; 22(1):1-16. PubMed ID: 15963074
[TBL] [Abstract][Full Text] [Related]
26. Bioequivalence of azathioprine products.
Baker DE
Rev Gastroenterol Disord; 2003; 3(4):219-23. PubMed ID: 14668694
[TBL] [Abstract][Full Text] [Related]
27. Azathioprine, 6-mercaptopurine and thiopurine S-methyltransferase.
Roberts-Thomson IC; Butler WJ
J Gastroenterol Hepatol; 2005 Jun; 20(6):955. PubMed ID: 15946151
[No Abstract] [Full Text] [Related]
28. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription.
Fargher EA; Tricker K; Newman W; Elliott R; Roberts SA; Shaffer JL; Bruce I; Payne K
J Clin Pharm Ther; 2007 Apr; 32(2):187-95. PubMed ID: 17381669
[TBL] [Abstract][Full Text] [Related]
29. Do ITPA and TPMT genotypes predict the development of side effects to AZA?
Duley JA; Marinaki AM; Arenas M; Florin TH
Gut; 2006 Jul; 55(7):1048; author reply 1048-9. PubMed ID: 16766757
[No Abstract] [Full Text] [Related]
30. Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.
Winter JW; Gaffney D; Shapiro D; Spooner RJ; Marinaki AM; Sanderson JD; Mills PR
Aliment Pharmacol Ther; 2007 May; 25(9):1069-77. PubMed ID: 17439508
[TBL] [Abstract][Full Text] [Related]
31. Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice.
de Boer NK; Mulder CJ; van Bodegraven AA
Aliment Pharmacol Ther; 2006 Apr; 23(8):1278-9; author reply 1279-80. PubMed ID: 16611294
[No Abstract] [Full Text] [Related]
32. Optimization and individualization of thiopurine therapy in inflammatory bowel disease: the great variability among drug responses.
Scherl E; Subbaramiah K
Pharmacogenomics J; 2003; 3(2):66-8. PubMed ID: 12746731
[No Abstract] [Full Text] [Related]
33. Review article: interactions between genotype and response to therapy in inflammatory bowel diseases.
Herrlinger KR; Jewell DP
Aliment Pharmacol Ther; 2006 Nov; 24(10):1403-12. PubMed ID: 17081161
[TBL] [Abstract][Full Text] [Related]
34. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary.
Griffiths AM
Inflamm Bowel Dis; 2003 Nov; 9(6):389-91; discussion 392-3. PubMed ID: 14671489
[No Abstract] [Full Text] [Related]
35. Thiopurine S-methyltransferase: a genetic polymorphism that affects a small number of drugs in a big way.
Evans WE
Pharmacogenetics; 2002 Aug; 12(6):421-3. PubMed ID: 12172209
[No Abstract] [Full Text] [Related]
36. [Azathioprine also in chronic active ulcerative colitis. Brake pedal for the immune system].
MMW Fortschr Med; 2000 Mar; 142(12):58-9. PubMed ID: 10804723
[No Abstract] [Full Text] [Related]
37. 6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP.
George P; Roberts R; Pike L
N Z Med J; 2003 Jul; 116(1178):U531. PubMed ID: 12901364
[No Abstract] [Full Text] [Related]
38. 6-thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP.
Gearry R; Barclay M; Gardiner S; Zhang M
N Z Med J; 2003 Jul; 116(1178):U531. PubMed ID: 12897892
[No Abstract] [Full Text] [Related]
39. Azathioprine-induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis.
Ben Ari Z; Mehta A; Lennard L; Burroughs AK
J Hepatol; 1995 Sep; 23(3):351-4. PubMed ID: 8551001
[TBL] [Abstract][Full Text] [Related]
40. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
